As a member of human milk oligosaccharides, lactodifucotetraose (LDFT) has shown some potential beneficial activities, attracting more and more attention from scientists. As a professional and authorization platform, CD BioGlyco supplies sufficient inventory of LDFT and a strong after-sales guarantee.

The Anti-inflammatory Ability of LDFT

In recent decades, research on human milk has proved that it can strongly inhibit inflammation in vitro. Breastfed infants are less likely to suffer from inflammatory diseases than artificially-fed infants. For newborns, the vulnerable populations, their platelets have a weak response to platelet agonists (such as thrombin and adrenaline). In the process of breastfeeding, oligosaccharides in human milk are not easy to digest, they enter the intestinal circulation, thus protecting the balance of intestinal flora and inhibiting the intestinal inflammatory process. In recent years, it has been reported that LDFT can reduce platelet function and release inflammatory cytokines. In the test results, only LDFT in purified human milk oligosaccharides apparently inhibited the release of thrombin-induced inflammatory proteins. At the same time, LDFT also inhibits the adhesion of platelets to the surface of collagen coating and the platelet aggregation induced by collagen or ADP. It can be speculated that LDFT may inhibit platelet-induced inflammation in infants to help regulate hemostasis.

Fig.1 LDFT inhibition of thrombin-induced release. (Newburg, et al., 2016)

OtherBiological Effects of LDFT

HMOs always have a positive effect on the growth of microbiota bacteria. When fed with 2'-fucosyllactose, 3-fucosyllactose, and LDFT, Bifidobacterium, and Bacteroides grow and produce short-chain fatty acid or rich lactate.

On the other hand, LDFT is positively correlated with HOMA index and insulin, which can help to further explore the glucose metabolism of obese pregnant women.

LDFT Production Service at CD BioGlyco

CD BioGlyco has accumulated a variety of Production solutions to meet changing client needs, including but not limited to the following technologies. It is hereby declared that the LDFT we offer should only be used as laboratory reagents for research and development.

• Optimized and mature separation and purification technology.
• Enzymatic synthesis
  Selection and identification of suitable enzymes.
  Identification of genes and inhibition or increase of corresponding gene expression.
• Microbial Fermentation
  Constructing engineered Escherichia coli.
  Using bacterial fucosyltransferases, low-cost substrates Selection, etc. to conduct microbial production.
  The metabolic pathway is optimized through genome fine-tuning, overexpression, and other strategies.
  The fed-batch cultivation of the strains.

Advantages of Us

• Response specificity.
• Efficient and high-yield production.
• Rich resources of enzyme resources.
• Combination of multi-disciplinary technologies
  Including protein engineering, metabolic engineering, and synthetic biology strategies and tools.

Through long-term experiments and research, CD BioGlyco is at the leading level in the world for the application of LDFT synthesis methods. If you need any further information, please feel free to contact us.

Reference:

1. Newburg, D.S.; et al. Lactodifucotetraose, a human milk oligosaccharide, attenuates platelet function and inflammatory cytokine release. Journal of thrombosis and thrombolysis. 2016, 42: 46-55.